Retinoic Acid Receptor Beta - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H1 2019’, provides in depth analysis on Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Gastrointestinal, Respiratory, Central Nervous System, Hematological Disorders, Immunology, Metabolic Disorders, Oncology and Ophthalmology under development targeting Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)

- The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects

- The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

Advent Therapeutics Inc

Bausch Health Companies Inc

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies ...

3SBio Inc

Advent Therapeutics Inc

Bausch Health Companies Inc

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

Sveikatal Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Overview

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Companies Involved in Therapeutics Development

3SBio Inc

Advent Therapeutics Inc

Bausch Health Companies Inc

Lee's Pharmaceutical Holdings Ltd

Orphanix GmbH

Ortho Dermatologics Inc

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

Sveikatal Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Drug Profiles

(adapalene + benzoyl peroxide + clindamycin phosphate) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(adapalene + clindamycin hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clindamycin phosphate + tretinoin) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(TPX-6001 + tretinoin) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-261066 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCL-286 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBD-073 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Dormant Products

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Discontinued Products

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) – Product Development Milestones

Featured News & Press Releases

Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris

Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425

Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris

Dec 02, 2018: Syros announces promising clinical data from ongoing phase 2 trial of SY-1425 in genomically defined AML and MDS patients at ASH Annual Meeting

Nov 01, 2018: Syros to present initial clinical data from combination cohorts in its ongoing phase 2 Trial of SY-1425 at ASH annual meeting

Oct 30, 2018: Bausch Health launches ALTRENO (tretinoin) Lotion, 0.05% in the United States

Oct 15, 2018: Bausch Health's ortho dermatologics business to present on ALTRENO During The Fall Clinical Dermatology Conference

Oct 11, 2018: Bausch Health announces publication of pivotal phase 3 efficacy and safety data on ALTRENO (tretinoin) Lotion, 0.05%, in the journal of drugs in dermatology

Sep 04, 2018: Sol-Gel Technologies provides program update for TWIN for the treatment of acne vulgaris

Aug 24, 2018: Ortho Dermatologics receives FDA approval for Altreno (tretinoin 0.05%) lotion for acne

Jul 10, 2018: Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

Feb 15, 2018: Sol-Gel’s Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting

Jan 22, 2018: Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARa Agonist

Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by 3SBio Inc, H1 2019

Pipeline by Advent Therapeutics Inc, H1 2019

Pipeline by Bausch Health Companies Inc, H1 2019

Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019

Pipeline by Orphanix GmbH, H1 2019

Pipeline by Ortho Dermatologics Inc, H1 2019

Pipeline by Phosphagenics Ltd, H1 2019

Pipeline by Promius Pharma LLC, H1 2019

Pipeline by Sol-Gel Technologies Ltd, H1 2019

Pipeline by Sunny BioDiscovery Inc, H1 2019

Pipeline by Sveikatal Inc, H1 2019

Pipeline by TherapyX Inc, H1 2019

Pipeline by Toko Pharmaceutical Industries Co Ltd, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports